AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22550143 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional public service announcement (PSA)
Number of subjects: 0
Study 22550143 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative fact appeal
Number of subjects: 0
Study 22550143 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive fact appeal
Number of subjects: 0
Study 22550143 — intervention group
Group type: EXPERIMENTAL
Intervention: Information sources
Number of subjects: 0
Study 19490551 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 8221
Study 19490551 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 8221
Study 19490551 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 8221
Study 17131169 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg
Number of subjects: 0
Study 17131169 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg
Number of subjects: 0
Study 17131169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17131169 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin (both doses)
Number of subjects: 0
Study 17131169 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 0
Study 15213046 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimicronutrient supplementation
Number of subjects: 1669
Study 15213046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1669
Study 11603453 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (10 mg/kg) 4 hours preoperatively
Number of subjects: 50
Study 11603453 — intervention group
Group type: COMPARATOR
Intervention: Control group (no steroid administration)
Number of subjects: 50
Study 9847641 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% tetracaine drops and intravenous fentanyl and propofol with continuous sedation (Group I)
Number of subjects: 260
Study 9847641 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine in the retrobulbar space and hypnotic doses of intravenous propofol (Group II)
Number of subjects: 260
Study 8079969 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprophane hemodialysis
Number of subjects: 10
Study 8079969 — intervention group
Group type: COMPARATOR
Intervention: Polyamide hemodialysis (control)
Number of subjects: 10
Study 2634902 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg twice daily)
Number of subjects: 7
Study 2634902 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg i.v.)
Number of subjects: 7
Study 2634902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 712981 — intervention group
Group type: EXPERIMENTAL
Intervention: Megavitamin combination
Number of subjects: 31
Study 712981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 29843843 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.0 cm/hen
Number of subjects: 60
Study 29843843 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.5 cm/hen
Number of subjects: 60
Study 29843843 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.5 cm/hen
Number of subjects: 60
Study 29843843 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5 cm/hen
Number of subjects: 60
Study 28622634 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary FSH
Number of subjects: 90
Study 28622634 — intervention group
Group type: EXPERIMENTAL
Intervention: hMG
Number of subjects: 90
Study 28622634 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FSH
Number of subjects: 90
Study 25684006 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl group (0.5% hyperbaric bupivacaine 0.2 mL + fentanyl 20 μg + 5% dextrose 1.4 mL)
Number of subjects: 56
Study 25684006 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil group (0.5% hyperbaric bupivacaine 0.2 mL + sufentanil 5 μg + 5% dextrose 1.7 mL)
Number of subjects: 56
Study 23764624 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental PrEP regimens (specifics not provided)
Number of subjects: 0
Study 23764624 — intervention group
Group type: COMPARATOR
Intervention: FTC/TDF (emtricitabine/tenofovir)
Number of subjects: 0
Study 23764624 — intervention group
Group type: EXPERIMENTAL
Intervention: New PrEP product with potential for higher adherence and potency (specifics not provided)
Number of subjects: 0
Study 19933540 — intervention group
Group type: EXPERIMENTAL
Intervention: Meds‐Help (pharmacy-based intervention)
Number of subjects: 118
Study 19933540 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 118
Study 19761135 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 kcal/d immun‐enhancing enteral nutrition (IEN)
Number of subjects: 50
Study 19761135 — intervention group
Group type: COMPARATOR
Intervention: 1000 kcal/d standard enteral nutrition
Number of subjects: 50
Study 17931382 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP plasma levels low (< 100 pg mL(‐1))
Number of subjects: 452
Study 17931382 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP plasma levels intermediate (100-500 pg mL(‐1))
Number of subjects: 452
Study 17931382 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP plasma levels high (> 500 pg mL(‐1))
Number of subjects: 452
Study 17931382 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP concentration
Number of subjects: 452
Study 17931382 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP plasma levels in non-cardiac causes
Number of subjects: 452
Study 17931382 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP plasma levels in cardiac causes
Number of subjects: 452
Study 15230644 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6mg twice daily
Number of subjects: 0
Study 15230644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15230644 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod
Number of subjects: 0
Study 11700404 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin 300,000 units
Number of subjects: 48
Study 11700404 — intervention group
Group type: COMPARATOR
Intervention: Blood transfusion
Number of subjects: 48
Study 9219678 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyalgan (500-730 kDa molecular weight), three cycles of three intra-articular injections (once a week during 2 weeks) every 3 months
Number of subjects: 39
Study 9219678 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional therapy)
Number of subjects: 39
Study 9219678 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyalgan
Number of subjects: 39
Study 9219678 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 8424294 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (1 mg.kg‐1 i.v. preoperatively, followed by 1.5 mg.kg‐1 infusion over 9 h)
Number of subjects: 40
Study 8424294 — intervention group
Group type: COMPARATOR
Intervention: Control (corresponding volumes of solvent)
Number of subjects: 40
Study 8424294 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 40
Study 8424294 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 8424294 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 3631499 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer program for calculating allowable blood loss
Number of subjects: 80
Study 3631499 — intervention group
Group type: COMPARATOR
Intervention: Standard method using blood volume estimated on a volume per weight basis
Number of subjects: 80
Study 31631741 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 8 years
Number of subjects: 124
Study 31631741 — intervention group
Group type: EXPERIMENTAL
Intervention: Ages 8 to 12 years
Number of subjects: 124
Study 31631741 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls
Number of subjects: 124
Study 31631741 — intervention group
Group type: EXPERIMENTAL
Intervention: Teasing and prosocial lies interpretation
Number of subjects: 124
Study 29614243 — intervention group
Group type: EXPERIMENTAL
Intervention: HP/TAZ lotion (halobetasol propionate 0.01% plus tazarotene 0.045%)
Number of subjects: 418
Study 29614243 — intervention group
Group type: EXPERIMENTAL
Intervention: HP/TAZ lotion
Number of subjects: 418
Study 29614243 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 418
Study 27037169 — intervention group
Group type: COMPARATOR
Intervention: 10 mL 2% Carbocaine lidocaine gel with 1 mL 0.9% saline (group 1)
Number of subjects: 0
Study 27037169 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL 5% NaHCO3 solution (group 2)
Number of subjects: 0
Study 24997651 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g dose of tranexamic acid (Group 1)
Number of subjects: 60
Study 24997651 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg dose of tranexamic acid (Group 2)
Number of subjects: 60
Study 24997651 — intervention group
Group type: COMPARATOR
Intervention: Control group (25 patients)
Number of subjects: 60
Study 22040403 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthodontic stent with 3D imaging (study group)
Number of subjects: 41
Study 22040403 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stent, conventional techniques)
Number of subjects: 41
Study 20552368 — intervention group
Group type: EXPERIMENTAL
Intervention: Open tension-free mesh-plug hernia technique
Number of subjects: 164
Study 20552368 — intervention group
Group type: COMPARATOR
Intervention: Transabdominal preperitoneal (TAPP) technique
Number of subjects: 164
Study 20552368 — intervention group
Group type: COMPARATOR
Intervention: Totally extraperitoneal (TEP) technique
Number of subjects: 164
Study 18211278 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized mental health consultation focused on behaviorally-based strategies for decreasing disruptive behaviors
Number of subjects: 96
Study 18211278 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized mental health consultation
Number of subjects: 96
Study 18211278 — intervention group
Group type: COMPARATOR
Intervention: Assessment/attention comparison group with typical treatment available
Number of subjects: 96
Study 16797163 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 21
Study 16797163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 12949850 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 1 to 3 mg/day
Number of subjects: 176
Study 12949850 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine 5 to 20 mg/day
Number of subjects: 176
Study 10966692 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group A)
Number of subjects: 125
Study 10966692 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral temazepam (group B)
Number of subjects: 125
Study 10966692 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam (group C)
Number of subjects: 125
Study 10966692 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam and fentanyl (group D)
Number of subjects: 125
Study 8990802 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g of calcium/day for 4 weeks
Number of subjects: 0
Study 8990802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1389813 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane at 0.0 MAC
Number of subjects: 8
Study 1389813 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at 0.1 MAC
Number of subjects: 8
Study 1389813 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at 0.2 MAC
Number of subjects: 8
Study 1389813 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at 0.4 MAC
Number of subjects: 8
Study 2420105 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 70
Number of subjects: 65
Study 2420105 — intervention group
Group type: COMPARATOR
Intervention: Dextran 70 + Dihydroergotamine
Number of subjects: 65
Study 30914044 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed antibiotic prescription (DAP)
Number of subjects: 215
Study 30914044 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed antibiotic prescription (DAP) for respiratory tract infections (RTIs)
Number of subjects: 215
Study 30914044 — intervention group
Group type: COMPARATOR
Intervention: Participation in the DAP RCT
Number of subjects: 215
Study 30914044 — intervention group
Group type: COMPARATOR
Intervention: Previous use of DAP
Number of subjects: 215
Study 30914044 — intervention group
Group type: COMPARATOR
Intervention: Profession type (physician vs nurse)
Number of subjects: 215
Study 30413542 — intervention group
Group type: COMPARATOR
Intervention: Mailed letter
Number of subjects: 5270
Study 30413542 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone call
Number of subjects: 5270
Study 26317322 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus paclitaxel
Number of subjects: 223
Study 26317322 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus paclitaxel
Number of subjects: 223
Study 25266473 — intervention group
Group type: EXPERIMENTAL
Intervention: Humor skill training
Number of subjects: 30
Study 25266473 — intervention group
Group type: COMPARATOR
Intervention: Control (doing handwork)
Number of subjects: 30
Study 22782352 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg daily for 14 days
Number of subjects: 15
Study 22782352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 20107799 — intervention group
Group type: EXPERIMENTAL
Intervention: Suramin plus docetaxel 75 mg/m²
Number of subjects: 18
Study 20107799 — intervention group
Group type: EXPERIMENTAL
Intervention: Suramin plus docetaxel 56 mg/m²
Number of subjects: 18
Study 20107799 — intervention group
Group type: EXPERIMENTAL
Intervention: Suramin plus gemcitabine 1,250 mg/m²
Number of subjects: 18
Study 20107799 — intervention group
Group type: EXPERIMENTAL
Intervention: Suramin (general)
Number of subjects: 18
Study 18485031 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspension technique
Number of subjects: 60
Study 18485031 — intervention group
Group type: COMPARATOR
Intervention: No suspension technique
Number of subjects: 60
Study 16269000 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic Complete (SC) toothbrush
Number of subjects: 34
Study 16269000 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonicare Elite (SE) toothbrush
Number of subjects: 34
Study 16269000 — intervention group
Group type: COMPARATOR
Intervention: Both brushes
Number of subjects: 34
Study 12122554 — intervention group
Group type: EXPERIMENTAL
Intervention: SSM+ (semisolid meal with 2.5 g GG)
Number of subjects: 15
Study 12122554 — intervention group
Group type: EXPERIMENTAL
Intervention: SM (solid meal)
Number of subjects: 15
Study 12122554 — intervention group
Group type: EXPERIMENTAL
Intervention: SSM+
Number of subjects: 15
Study 12122554 — intervention group
Group type: EXPERIMENTAL
Intervention: SM
Number of subjects: 15
Study 12122554 — intervention group
Group type: COMPARATOR
Intervention: SSM
Number of subjects: 15
Study 10774648 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-impregnated bed nets
Number of subjects: 0
Study 7494721 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication group program aimed at diminishing affective components of negative attitudes towards neuroleptics
Number of subjects: 0
Study 7494721 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 2089252 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose calcitriol (0.25 microgram b.i.d.) and 1 g of supplemental calcium therapy
Number of subjects: 4
Study 2089252 — intervention group
Group type: COMPARATOR
Intervention: Ergocalciferol (50,000 units twice a week) and 1 g of supplemental calcium
Number of subjects: 4
Study 360761 — intervention group
Group type: EXPERIMENTAL
Intervention: Deanol
Number of subjects: 10
Study 360761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30470666 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (EG): moderate aerobic exercise performed three days per week (50‐55 minutes per session) for 8‐10 weeks to 38‐39 weeks gestation.
Number of subjects: 456
Study 30470666 — intervention group
Group type: COMPARATOR
Intervention: Standard care control (CG): no specific intervention mentioned.
Number of subjects: 456
Study 29097659 — intervention group
Group type: EXPERIMENTAL
Intervention: Model A educational intervention (three-stage)
Number of subjects: 1690
Study 29097659 — intervention group
Group type: EXPERIMENTAL
Intervention: Model B educational intervention (two-stage)
Number of subjects: 1690
Study 29097659 — intervention group
Group type: EXPERIMENTAL
Intervention: Model C educational intervention (one-stage)
Number of subjects: 1690
Study 25979441 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal vitamin A supplementation
Number of subjects: 31999
Study 25979441 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal period
Number of subjects: 31999
Study 25979441 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 6-12 months
Number of subjects: 31999
Study 25979441 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and socioeconomic factors
Number of subjects: 31999
Study 25979441 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental factors
Number of subjects: 31999
Study 23001254 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued ecstasy and/or amphetamine use (n=17)
Number of subjects: 40
Study 23001254 — intervention group
Group type: COMPARATOR
Intervention: Stopped ecstasy and/or amphetamine use (n=12)
Number of subjects: 40
Study 23001254 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 21586821 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDCS (2 mA for 20 min)
Number of subjects: 10
Study 21586821 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (2 mA for 1 min)
Number of subjects: 10
Study 19321575 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g/d seaweed (Alaria)
Number of subjects: 15
Study 19321575 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy supplementation
Number of subjects: 15
Study 19321575 — intervention group
Group type: EXPERIMENTAL
Intervention: Seaweed plus soy (SeaSoy)
Number of subjects: 15
Study 19321575 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy for equol excretors
Number of subjects: 15
Study 19321575 — intervention group
Group type: EXPERIMENTAL
Intervention: SeaSoy for equol producers
Number of subjects: 15
Study 16481636 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D supplementation (500 mg of elemental calcium as calcium carbonate with 200 IU of vitamin D3 twice daily for an average of 7.0 years)
Number of subjects: 36282
Study 16481636 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo for an average of 7.0 years)
Number of subjects: 36282
Study 15503798 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific vestibular exercises
Number of subjects: 58
Study 15503798 — intervention group
Group type: COMPARATOR
Intervention: Non-specific exercises
Number of subjects: 58
Study 11382835 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascupump treatment (20 sessions of 45 minutes each)
Number of subjects: 36
Study 11382835 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with Vascupump and Pentoxillin (3 fl/per diem for 20 days)
Number of subjects: 36
Study 11382835 — intervention group
Group type: COMPARATOR
Intervention: Pentoxillin alone (3 n per diem for 20 days)
Number of subjects: 36
Study 9745422 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human IGF‐I (60 micrograms/kg), i.v., over 4 h
Number of subjects: 8
Study 8058074 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg twice daily)
Number of subjects: 143
Study 8058074 — intervention group
Group type: COMPARATOR
Intervention: Digoxin (0.25 mg daily)
Number of subjects: 143
Study 8058074 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 143
Study 8058074 — intervention group
Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 143
Study 3405354 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery (within 72 hours)
Number of subjects: 356
Study 3405354 — intervention group
Group type: COMPARATOR
Intervention: Late surgery (after 72 hours)
Number of subjects: 356
Study 3405354 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery (stages IV and V)
Number of subjects: 356
Study 3405354 — intervention group
Group type: COMPARATOR
Intervention: Late surgery (stages IV and V)
Number of subjects: 356
Study 3405354 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery
Number of subjects: 356
Study 3405354 — intervention group
Group type: COMPARATOR
Intervention: Late surgery
Number of subjects: 356
Study 31231136 — intervention group
Group type: EXPERIMENTAL
Intervention: Massively parallel shotgun sequencing (semiconductor-based)
Number of subjects: 4000
Study 31231136 — intervention group
Group type: EXPERIMENTAL
Intervention: Massively parallel shotgun sequencing (optical-based)
Number of subjects: 4000
Study 31231136 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sequencing platforms
Number of subjects: 4000
Study 28508579 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Coaching (TC)
Number of subjects: 37
Study 28508579 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 37
Study 26375689 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 receptor agonist liraglutide
Number of subjects: 0
Study 24660607 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (10 sessions of puncturing acupuncture at various acupoints including Hegu (LI 4))
Number of subjects: 0
Study 24660607 — intervention group
Group type: COMPARATOR
Intervention: Self-pressing right-hand Hegu (LI 4)
Number of subjects: 0
Study 22180716 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hepatectomy
Number of subjects: 60
Study 22180716 — intervention group
Group type: COMPARATOR
Intervention: Open hepatectomy
Number of subjects: 60
Study 18299944 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic total fundoplication
Number of subjects: 167
Study 18299944 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic anterior fundoplication
Number of subjects: 167
Study 16442211 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin OCAS 0.4 mg
Number of subjects: 58
Study 16442211 — intervention group
Group type: COMPARATOR
Intervention: Alfuzosin XL 10 mg
Number of subjects: 58